Clinical Trials Browser

Phase 3 × Active not recruiting × Carcinoma, Renal Cell × Clear all

NCT03091192 2026-04-14

Savolitinib vs. Sunitinib in MET-driven PRCC.

Phase 3 Active not recruiting

60 enrolled 15 charts

Carcinoma, Carcinoma, Renal Cell, Kidney Diseases, Kidney Neoplasms, Neoplasms by Site, Urologic Neoplasms

NCT01575548 2026-04-13

Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery

Phase 3 Active not recruiting

129 enrolled 11 charts

Carcinoma, Renal Cell

NCT03055013 2026-04-13

Nivolumab in Treating Patients With Localized Kidney Cancer Undergoing Nephrectomy

Phase 3 Active not recruiting

819 enrolled 12 charts

Carcinoma, Renal Cell

NCT03793166 2026-04-13

Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study

Phase 3 Active not recruiting

Carcinoma, Renal Cell, Lymphatic Metastasis

NCT05863351 2026-04-03

Focused Radiation Versus Systemic Therapy for Kidney Cancer Patients With Limited Metastasis, SOAR Study

Phase 3 Active not recruiting

Carcinoma, Renal Cell

NCT03815643 2026-03-31

Avelumab Program Rollover Study

Phase 3 Active not recruiting

GenitourinaryGynecologicThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Ovarian Neoplasms

NCT07000149 2026-03-10

eVOLVE-RCC02

Phase 3 Active not recruiting

Diabetes Mellitus, Insulin-Dependent, 12, Carcinoma, Renal Cell, Kidney Neoplasms

NCT04586231 2026-03-05

MK-6482-011

Phase 3 Active not recruiting

Carcinoma, Renal Cell

NCT02811861 2026-02-23

CLEAR

Phase 3 Active not recruiting

1,069 enrolled 12 charts 2 FDA

Carcinoma, Renal Cell

NCT03873402 2026-01-21

A Study of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Participants With Advanced Kidney Cancer

Phase 3 Active not recruiting

Carcinoma, Renal Cell

NCT01224288 2025-11-10

Dynamic Contrast Enhancement Computed Tomography for Evaluating Tumor Perfusion in Patients With Metastatic Renal Cell Carcinoma Receiving Targeted Therapies: Renal Cell Carcinoma (RCC) Scramble

Phase 3 Active not recruiting

Carcinoma, Renal Cell, Kidney Neoplasms

NCT05899049 2025-11-10

A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, vs Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)-China Extension Study

Phase 3 Active not recruiting

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Renal Cell

NCT04810078 2025-10-09

CheckMate-67T

Phase 3 Active not recruiting

681 enrolled 3 FDA

Carcinoma, Renal Cell

NCT03937219 2025-09-10

COSMIC-313

Phase 3 Active not recruiting

855 enrolled 12 charts

Carcinoma, Carcinoma, Renal Cell, Neoplasms

NCT04987203 2025-08-22

Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma

Phase 3 Active not recruiting

Carcinoma, Renal Cell, Disease Progression

NCT05239728 2025-08-14

MK-6482-022

Phase 3 Active not recruiting

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Renal Cell

NCT03141177 2025-06-06

CheckMate 9ER

Phase 3 Active not recruiting

701 enrolled 17 charts 2 FDA

Carcinoma, Renal Cell

NCT05219318 2025-06-04

SPICI

Phase 3 Active not recruiting

Carcinoma, Renal Cell

NCT05043090 2025-05-08

SAMETA

Phase 3 Active not recruiting

Carcinoma, Carcinoma, Renal Cell, Neoplasm Metastasis

NCT04195750 2025-04-29

A Study of Belzutifan (MK-6482) Versus Everolimus in Participants With Advanced Renal Cell Carcinoma (MK-6482-005)

Phase 3 Active not recruiting

755 enrolled 28 charts 2 FDA

Carcinoma, Renal Cell, Kidney Neoplasms

NCT04736706 2024-11-18

MK-6482-012

Phase 3 Active not recruiting

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Renal Cell